Dimitrios Tzivelis
Senior Principal
Get their honest, personalized take on your startup.
Sign in to pitch Dimitrios →At a glance
- Full Name
- Dimitrios Tzivelis
- Title
- Managing Director (formerly Senior Principal at Onex, 2018–2021)
- Firm
- Permira (Permira Advisers LLP)
- Firm Type
- Private equity / buyout (not angel investing — see note below)
- Investment Stage
- Large-cap and growth buyouts / control equity — not seed-stage
- Check Size
- Institutional buyout equity (Permira funds have >€80bn AUM; transactions he has led run from hundreds of millions to multi-billion in enterprise value)
- Target Company Profile
- Established, scaled healthcare businesses — plasma/biopharma, contract development and manufacturing (CDMO), and diagnostics/radiology platforms
- Sector Focus
- Healthcare (his dedicated vertical across BC Partners, Onex, and Permira)
- Geographic Focus
- Europe, with pan-global healthcare mandates (deals across Italy, UK, and APAC)
- Location
- London, United Kingdom
Background
Dimitrios Tzivelis is a London-based private equity investor specializing in the healthcare sector. He is currently a Managing Director at Permira, the global private equity firm with combined assets under management of over €80 billion. Before joining Permira (2021), he spent roughly three years as a Senior Principal at Onex (March 2018–August 2021), where he led the firm's healthcare investments across Europe. Prior to Onex, he spent about nine years at BC Partners, also focused on healthcare, and began his finance career as an investment banking associate at Credit Suisse and an analyst at Lehman Brothers, working in London and Milan.
His academic credentials are exceptionally strong: an MBA with Distinction from Harvard Business School, a Master of Science in Corporate Finance *summa cum laude* from Bocconi University in Milan, and a Bachelor's in Business Administration with academic honors from LUISS University in Rome.
At Permira he sits on the boards of Kedrion Biopharma and Quotient Sciences and has been involved in the firm's largest healthcare platforms. He is an active voice in the healthcare-investing community, appearing at industry events such as the Sidley Healthcare Investment Conference and NOVA MBA healthcare panels, and gave a Private Equity International (PEI) keynote interview in 2024 on integrating technology into the healthcare value chain.
Investment Thesis & Focus
- Sector specialist in healthcare — his entire career (BC Partners → Onex → Permira) has been dedicated to healthcare investing, giving him deep domain focus rather than generalist coverage.
- Control-oriented buyouts of scaled platforms, not early-stage venture or angel checks. Targets include plasma/biopharma manufacturers, pharma services/CDMOs, and diagnostic-imaging networks.
- Thematic interest in technology within healthcare delivery — the subject of his 2024 PEI keynote, "Integrating tech into the healthcare value chain," signaling a thesis around modernizing and digitizing established healthcare businesses.
- Buy-and-build / consolidation plays — e.g., the combination of Kedrion and Bio Products Laboratory (BPL) into a single plasma-derived therapeutics group.
- Says "yes" to businesses with defensible market positions, regulatory moats, and clear operational value-creation and roll-up potential.
Notable Investments
- Kedrion Biopharma (Italy) — Plasma-derived biotherapeutics maker; Permira and the Marcucci family invested in 2022 and merged it with UK-based Bio Products Laboratory (BPL). Tzivelis serves on the board.
- Quotient Sciences (UK) — Drug development and manufacturing (CDMO) services company; acquired by Permira funds (announced 2019, ~$752M). Tzivelis serves on the board.
- I-MED Radiology Network (Australia / APAC) — Diagnostic imaging provider; Permira funds agreed to acquire it in 2024 (Permira later agreed to sell I-MED to Jardine Matheson, announced 2026).
- Bio Products Laboratory (BPL) (UK) — Plasma products manufacturer combined with Kedrion under Permira ownership (2022).
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.